Chemomab Therapeutics (CMMB) to Release Quarterly Earnings on Monday

Chemomab Therapeutics (NASDAQ:CMMB) is anticipated to announce its Q4 2025 results before the market opens on Monday, March 2nd. Analysts expect the company to announce earnings of ($0.20) per share for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Friday, March 6, 2026 at 7:00 AM ET.

Chemomab Therapeutics Price Performance

NASDAQ CMMB opened at $1.57 on Monday. The firm has a market capitalization of $9.67 million, a price-to-earnings ratio of -0.53 and a beta of 0.56. The company has a 50 day simple moving average of $1.71 and a 200-day simple moving average of $2.53. Chemomab Therapeutics has a 52-week low of $1.40 and a 52-week high of $7.08.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Chemomab Therapeutics stock. XTX Topco Ltd acquired a new position in Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 19,013 shares of the company’s stock, valued at approximately $31,000. XTX Topco Ltd owned approximately 0.31% of Chemomab Therapeutics at the end of the most recent quarter. 46.05% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on CMMB shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Chemomab Therapeutics in a research note on Monday, December 29th. Zacks Research cut Chemomab Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 18th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $25.00.

About Chemomab Therapeutics

Chemomab Therapeutics (NASDAQ:CMMB) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation antibody therapies. The company leverages a proprietary antibody engineering platform to generate novel bi- and multi-specific antibodies with applications in oncology, infectious diseases and inflammatory disorders. By combining cutting-edge discovery tools with translational research, Chemomab aims to advance promising candidates from early proof-of-concept through clinical development.

Among its pipeline programs, Chemomab is advancing antibody candidates designed to target key tumor antigens and pathogen-specific epitopes.